

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

**POLL RESULTS OF
THE 2025 FIRST EXTRAORDINARY GENERAL MEETING**

POLL RESULTS OF THE EGM

The Board of Directors hereby announces the poll results in respect of the resolutions proposed at the EGM on Thursday, October 23, 2025. All resolutions were duly passed by way of poll at the EGM.

GRANT OF H SHARE OPTIONS TO THE GRANTEES

The resolutions regarding the adoption of the 2025 H Share Option Scheme of the Company and the proposed grant of 371,300 H Share Options to Dr. Xuefeng YU were approved at the EGM. An aggregate of 860,000 H Share Options were granted to the two executive Directors (including Dr. Xuefeng YU and Dr. Shou Bai CHAO) and two senior management (including Dr. Tao ZHU and Dr. Dongxu QIU). For details, please refer to the announcement of the Company dated September 26, 2025.

CanSino Biologics Inc. (the “**Company**”) announces that at its 2025 first extraordinary general meeting (the “**EGM**”) held on Thursday, October 23, 2025, all resolutions proposed were duly passed by way of poll. The EGM was convened by the board (the “**Board of Directors**”) of directors (the “**Directors**”) of the Company.

Further details of the resolutions are set out in the notice of the EGM of the Company dated October 6, 2025 (the “**Notice**”) and the circular of the Company dated the same date (the “**Circular**”).

Unless the context otherwise requires, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

ATTENDANCE AT THE EGM

The Board of Directors is pleased to announce that the EGM was held at 2:00 p.m. on Thursday, October 23, 2025 at No. 1, Yuebin Hall, 2nd Floor, Hyatt Regency Tianjin East, No. 126 Weiguo Road, Hedong District, Tianjin, the PRC.

All Directors, Supervisors and senior management of the Company attended the EGM either in person or by means of telecommunication.

The attendance of the EGM is as follows:

Class of Shares	Number of Shares in issue (and entitling holders to attend and vote for or against any resolution)	Number of Shares present (in person or by proxy)	Approximate %
H Shares	132,670,900	47,557,687	35.85%
A Shares	<u>114,372,901⁽¹⁾</u>	<u>46,850,612</u>	<u>40.96%</u>
Total	<u>247,043,801</u>	<u>94,408,299</u>	<u>38.22%</u>

Note:

- (1) The total number of A Shares for calculating the attendance of the EGM does not include 406,098 A Shares repurchased and deposited in the share repurchase account of the Company as of the date of this announcement.

Save as disclosed in the Circular, to the best knowledge, information and belief of the Company: (i) there were no Shares entitling the holder to attend and abstain from voting in favor of the resolutions proposed at the EGM as set out in Rule 13.40 of the Hong Kong Listing Rules; (ii) no Shareholder was required under the Hong Kong Listing Rules to abstain from voting on the resolutions proposed at the EGM; and (iii) no party has stated any intention in the Circular to vote against or to abstain from voting on any of the resolutions proposed at the EGM.

POLL RESULTS OF THE EGM

The poll results of the EGM were as follows:

Special Resolutions ⁽¹⁾		For ⁽²⁾	Against ⁽²⁾	Abstain ⁽²⁾	Passed by Shareholders ⁽³⁾
1.	To consider and approve the proposed adoption of the 2025 A Share Incentive Scheme and the proposed issue of Restricted Shares under the 2025 A Share Incentive Scheme.	89,697,348 (95.0100%)	4,639,137 (4.9139%)	71,814 (0.0761%)	Yes
2.	To consider and approve the proposed adoption of the 2025 A Share Incentive Scheme Assessment Management Measures.	91,115,790 (96.5125%)	3,220,695 (3.4115%)	71,814 (0.0761%)	Yes
3.	To consider and approve the proposed authorization to the Board to deal with matters relating to the 2025 A Share Incentive Scheme.	89,701,548 (95.0145%)	4,634,937 (4.9095%)	71,814 (0.0761%)	Yes
4.	To consider and approve the proposed adoption of the 2025 H Share Option Scheme.	19,266,066 ⁽⁴⁾ (76.7221%)	5,773,118 (22.9899%)	72,315 (0.2880%)	Yes
5.	To consider and approve the proposed authorization to the Board to deal with matters relating to the 2025 H Share Option Scheme.	19,307,641 (76.8876%)	5,731,543 (22.8244%)	72,315 (0.2880%)	Yes
6.	To consider and approve the proposed grant of 371,300 H Share Options to Dr. Xuefeng YU.	19,289,491 (76.8154%)	5,740,844 (22.8614%)	81,164 (0.3232%)	Yes
7.	To consider and approve the proposed cancellation of Repurchased A Shares and reduction of registered capital.	94,188,353 (99.7713%)	129,082 (0.1367%)	86,864 (0.0920%)	Yes

Notes:

- (1) Please refer to the Notice and Circular for details of these resolutions.
- (2) All percentages rounded to four decimal places. The percentage figures included in this table have been subject to rounding adjustments.
- (3) A special resolution is passed by more than two-thirds of the votes casted in favor of it.
- (4) In respect of 11,083,517 H Shares held by Dr. Dongxu QIU through the Central Clearing and Settlement System, votes were cast in favour of the resolution numbered 4 regarding the proposed adoption of the 2025 H Share Option Scheme at the EGM due to an inadvertent error by the relevant broker. As Dr. Dongxu QIU was required to abstain from voting on this resolution, these votes have been disregarded. The exclusion of these votes did not affect the passing of the resolution.

GRANT OF H SHARE OPTIONS TO THE GRANTEES

The resolutions regarding the adoption of the 2025 H Share Option Scheme of the Company and the proposed grant of 371,300 H Share Options to Dr. Xuefeng YU were approved at the EGM. An aggregate of 860,000 H Share Options were granted to the two executive Directors (including Dr. Xuefeng YU and Dr. Shou Bai CHAO) and two senior management (including Dr. Tao ZHU and Dr. Dongxu QIU). For details, please refer to the announcement of the Company dated September 26, 2025.

SCRUTINEERS

The H share registrar of the Company, Computershare Hong Kong Investor Services Limited, acted as the scrutineer for the vote-taking at the EGM. Two representatives of the Shareholders, one lawyer of Jingtian & Gongcheng Law Firm, and one Supervisor participated in the scrutiny of the poll results.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, October 23, 2025

As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO and Ms. Jing WANG as executive Directors, Mr. Chi Shing LI as a non-executive Director, and Mr. Shuifa GUI, Mr. Jianzhong LIU and Mr. Yiu Leung Andy CHEUNG as independent non-executive Directors.